JP6918819B2 - オルトミクソウイルス感染の処置に有用な三環式化合物 - Google Patents
オルトミクソウイルス感染の処置に有用な三環式化合物 Download PDFInfo
- Publication number
- JP6918819B2 JP6918819B2 JP2018547307A JP2018547307A JP6918819B2 JP 6918819 B2 JP6918819 B2 JP 6918819B2 JP 2018547307 A JP2018547307 A JP 2018547307A JP 2018547307 A JP2018547307 A JP 2018547307A JP 6918819 B2 JP6918819 B2 JP 6918819B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- pharmaceutically acceptable
- ring
- benzyloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AJVXSKCJVFQMBZ-RUZDIDTESA-N C=[Br]c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 Chemical compound C=[Br]c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 AJVXSKCJVFQMBZ-RUZDIDTESA-N 0.000 description 1
- PHZVOXJWCROCGO-LJQANCHMSA-N CC(OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O)=O Chemical compound CC(OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O)=O PHZVOXJWCROCGO-LJQANCHMSA-N 0.000 description 1
- BKJAAHYPKYYXDR-OTOKDRCRSA-N CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)O Chemical compound CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)O BKJAAHYPKYYXDR-OTOKDRCRSA-N 0.000 description 1
- BZNXSEXRGLMSIC-RZIURPKCSA-N CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)O Chemical compound CC(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)O BZNXSEXRGLMSIC-RZIURPKCSA-N 0.000 description 1
- SEUGYZHGQXZGJU-UHFFFAOYSA-N CCC([n]1c2ncc1)N(C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O Chemical compound CCC([n]1c2ncc1)N(C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O SEUGYZHGQXZGJU-UHFFFAOYSA-N 0.000 description 1
- ZTWDNXGMOKHLGO-HXUWFJFHSA-N CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)=O Chemical compound CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O)=O ZTWDNXGMOKHLGO-HXUWFJFHSA-N 0.000 description 1
- JSZATNWYUXBKGW-HHHXNRCGSA-N CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)=O Chemical compound CN(C)C(c1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1)=O JSZATNWYUXBKGW-HHHXNRCGSA-N 0.000 description 1
- CYVDNIFUERLGCM-HXUWFJFHSA-N Cc1c(C)nc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O Chemical compound Cc1c(C)nc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1O CYVDNIFUERLGCM-HXUWFJFHSA-N 0.000 description 1
- FEVGXTBZUUITCJ-AREMUKBSSA-N O=Cc1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 Chemical compound O=Cc1cnc2[n]1C[C@H](C(c1ccccc1)c1ccccc1)N(C=CC1=O)C2=C1OCc1ccccc1 FEVGXTBZUUITCJ-AREMUKBSSA-N 0.000 description 1
- MHWFNXWCPQNGRQ-XMMPIXPASA-N OC1=C(c2ncc(-c3ccccc3)[n]2C[C@@H]2C(c3ccccc3)c3ccccc3)N2C=CC1=O Chemical compound OC1=C(c2ncc(-c3ccccc3)[n]2C[C@@H]2C(c3ccccc3)c3ccccc3)N2C=CC1=O MHWFNXWCPQNGRQ-XMMPIXPASA-N 0.000 description 1
- AWIJSMFVNDAWRA-UHFFFAOYSA-N OC1=C(c2ncc[n]2CC2C(c3cccc(Cl)c3)c3cc(Cl)ccc3)N2N=CC1=O Chemical compound OC1=C(c2ncc[n]2CC2C(c3cccc(Cl)c3)c3cc(Cl)ccc3)N2N=CC1=O AWIJSMFVNDAWRA-UHFFFAOYSA-N 0.000 description 1
- SHISIZVWEDLGHH-QGZVFWFLSA-N OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O Chemical compound OC1=C(c2ncc[n]2C[C@@H]2C(c(cc3)ccc3F)c(cc3)ccc3F)N2N=CC1=O SHISIZVWEDLGHH-QGZVFWFLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305392P | 2016-03-08 | 2016-03-08 | |
| US62/305,392 | 2016-03-08 | ||
| PCT/IB2017/051338 WO2017153919A1 (en) | 2016-03-08 | 2017-03-07 | Tricyclic compounds useful to treat orthomyxovirus infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512485A JP2019512485A (ja) | 2019-05-16 |
| JP2019512485A5 JP2019512485A5 (enExample) | 2020-05-28 |
| JP6918819B2 true JP6918819B2 (ja) | 2021-08-11 |
Family
ID=58347733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547307A Active JP6918819B2 (ja) | 2016-03-08 | 2017-03-07 | オルトミクソウイルス感染の処置に有用な三環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858366B2 (enExample) |
| EP (1) | EP3426656B1 (enExample) |
| JP (1) | JP6918819B2 (enExample) |
| CN (1) | CN108699059B (enExample) |
| ES (1) | ES2881776T3 (enExample) |
| WO (1) | WO2017153919A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4219508B1 (en) | 2015-04-28 | 2024-06-05 | Shionogi & Co., Ltd | Substituted polycyclic pyridone derivative and prodrug thereof |
| CR20180356A (es) | 2015-12-15 | 2018-08-22 | Shionogi & Co | Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza |
| CN109069488B (zh) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | 乙型肝炎抗病毒剂 |
| WO2017153919A1 (en) * | 2016-03-08 | 2017-09-14 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| NZ791086A (en) | 2016-08-10 | 2025-08-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| MY203207A (en) | 2018-02-28 | 2024-06-14 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN111410661B (zh) * | 2019-01-04 | 2023-05-05 | 周雨恬 | 帽依赖性内切核酸酶抑制剂及其用途 |
| CN109912624B (zh) * | 2019-04-11 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种巴洛沙韦酯关键母核中间体的合成方法 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| DE15187654T1 (de) | 2001-08-10 | 2016-12-01 | Shionogi & Co., Ltd | Antivirales Mittel |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) * | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| FR2901795A1 (fr) * | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| MX2011004636A (es) | 2008-10-31 | 2011-06-20 | Shionogi & Co | Cefarosporinas que tienen un grupo catecol. |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| EP2412708A4 (en) * | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| RS57244B1 (sr) * | 2009-06-15 | 2018-07-31 | Shionogi & Co | Supstituisani policiklički derivati karbamoilpiridona |
| WO2011123678A2 (en) * | 2010-03-31 | 2011-10-06 | Arqule, Inc. | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| RS57490B1 (sr) | 2010-09-24 | 2018-10-31 | Shionogi & Co | Supstituisani prolek derivata policikličnog karbamoil piridona |
| WO2012151567A1 (en) * | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| KR20140090197A (ko) | 2011-10-12 | 2014-07-16 | 시오노기세야쿠 가부시키가이샤 | 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체 |
| ES2604766T3 (es) | 2012-09-20 | 2017-03-09 | Celltrion, Inc. | Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo |
| AR094378A1 (es) * | 2013-01-08 | 2015-07-29 | Savira Pharmaceuticals Gmbh | Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral |
| NZ716822A (en) | 2013-08-21 | 2017-10-27 | Alios Biopharma Inc | Antiviral compounds |
| WO2015038665A1 (en) | 2013-09-11 | 2015-03-19 | University Of Southern California | A composition of stem cells having highly expressed fas ligand |
| KR102286860B1 (ko) | 2013-09-12 | 2021-08-05 | 얀센 바이오파마, 인코퍼레이트. | 피리다지논 화합물 및 이의 용도 |
| KR102323515B1 (ko) * | 2013-09-12 | 2021-11-05 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| CA2953862A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| MX383931B (es) | 2015-03-11 | 2025-03-14 | Janssen Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| WO2017153919A1 (en) | 2016-03-08 | 2017-09-14 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| NZ791086A (en) | 2016-08-10 | 2025-08-29 | Shionogi & Co | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| KR102477187B1 (ko) | 2018-01-17 | 2022-12-12 | 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드 | 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 |
| MY203207A (en) | 2018-02-28 | 2024-06-14 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
-
2017
- 2017-03-07 WO PCT/IB2017/051338 patent/WO2017153919A1/en not_active Ceased
- 2017-03-07 ES ES17711349T patent/ES2881776T3/es active Active
- 2017-03-07 CN CN201780015673.6A patent/CN108699059B/zh active Active
- 2017-03-07 US US16/083,089 patent/US10858366B2/en active Active
- 2017-03-07 JP JP2018547307A patent/JP6918819B2/ja active Active
- 2017-03-07 EP EP17711349.5A patent/EP3426656B1/en active Active
-
2020
- 2020-07-20 US US16/933,000 patent/US11453677B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3426656B1 (en) | 2021-05-12 |
| WO2017153919A1 (en) | 2017-09-14 |
| US10858366B2 (en) | 2020-12-08 |
| CN108699059B (zh) | 2021-06-18 |
| US11453677B2 (en) | 2022-09-27 |
| US20190092780A1 (en) | 2019-03-28 |
| JP2019512485A (ja) | 2019-05-16 |
| EP3426656A1 (en) | 2019-01-16 |
| US20200347072A1 (en) | 2020-11-05 |
| CN108699059A (zh) | 2018-10-23 |
| ES2881776T3 (es) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6918819B2 (ja) | オルトミクソウイルス感染の処置に有用な三環式化合物 | |
| US20250223288A1 (en) | Amino acid compounds and methods of use | |
| US11034685B2 (en) | Aminopyridine derivatives as TAM family kinase inhibitors | |
| CN113683614B (zh) | 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物 | |
| US8729271B2 (en) | Glycine transporter inhibiting substances | |
| US12071441B2 (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| HK40033744A (en) | Compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| HK40009791B (zh) | 用於治疗正粘病毒感染的稠合三环哒嗪酮化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200415 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210528 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210622 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210721 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6918819 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |